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dnym (57%) i tylko w 46% rak6w;
w wi~kszosci u tych chorych, u kt6rych
w pooperacyjnym badaniu histopatolo-
gicznym wykryto przerzuty do w~zt6w
chtonnych pachowych. Znacznie wi~kszq
nadekspresjq charakteryzowat si~ typ 0
sr6dbtonkowego czynnika wzrostu. U 75%
chorych na raka stwierdzono wyst~po­
wanie tej cytokiny proangiogennej zar6-
wno w jqdrach jak i cytoplazmie kom6rek.
Aktualnie testowanych jest oketo 20 spe-
cyfik6w, kt6rych mechanizm dziatania
polega na hamowaniu ekspresji r6znych
typ6w VEGF, majqcych punkty uchwytu
na r6znych receptorach 0 aktywnosci
kinazy tyrozynowej VEGFR-1,2,3. Stwarza
to nadziej~, ze w niedalekiej przysztosci
b~dzie mozna wytonic grup~ chorych
z nadekspresjq czynnik6w proangio-
gennych, u kt6rych terapia tymi lekami
zwi~kszy szans~ na wyleczenie z raka
piersi.
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INDUCTION OF THE DONOR SPE-
CIFIC CHIMERISM AND TOLERAN-
CE IN FULLY MHC MISMATCHED
LIMB ALLOGRAFT RECIPIENTS
Izycki D., Osawa T., Zielinski M.,
Ozer K., Mackiewicz A., Siemionow M.
Zaktad Immunologii Nowotwor6w AM
w Poznaniu, Department of Plastic Surgery,
The Cleveland Clinic Foundation
Purpose: Induction of donor-specific
tolerance in composite tissue allografts
(eTA) remains one of the most challenging
goals in transplant surgery. Recently
we have developed a protocol (ab TCR
mAbl CsA) for tolerance induction in the
semiallogeneic rat hifld..,Iimb .transplafl-
tationsl. In this report we induced tolerance
in the fully MHC mismatched allograft
recipients under, combined ab-TCR/CSA
protocol.
Methods: Thirty transplantations across
strong MHC barrier were performed
between Brown~Norway donors (RT1 n)
and LEW recipients. Isograft and allograft
rejection control groups received no
treatment. Experimental groups received
either rat abTCR or CsA or combination
of abTCR and CsA at the day of trans-
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plantation and for 7 days thereafter. The
efficacy of immunosuppressive treatment
and chimerism were monitored by flow
cytometry FC. Donor specific tolerance
and immunocompetence of the limb
recipients were determined in vivo by
secondary skin graft from the recipient
(LEW), the donor (BN) and the third party
(ACI) graft. Mixed lymphocyte reaction
(MLR) was performed for the assessment
of donor specific tolerance in vitro.
Results: Only fUlly mismatched allograft
recipients under abTCR/CsA protocol
survived indefinite (over 250 days). Three
color FC analysis at day 120 post-
transplant demonstrated stable, multi-
lineage, donor specific chimerism in the
periphery of the tolerated recipients
(CD4+PE/RT1 n+APC-7.6% and 1.3% of
CD8+PE/RT1 n+APC positive T cell sub-
populations and CD45RA+PE/RT1 n+APC-
16.5% B cell population). Donor specific
tolerance and immunocompetence in vivo
was confirmed by acceptance of the
secondary skin graft from the donor and
rejection of the third-party grafts. MLR
revealed no reactivity to host (LEW) and
donor (BN) antigens but strong reactivity to
the third- party alloantigens.
Conclusions: Donor specific tolerance
was induced under 7 days protocol of
abTCR/CsA therapy in the fully
mismatched limb allograft transplanrs.
Stable mixed chimerism was achieved
without the need for the myeloablative
bone marrow modification of the recipients
and without the need for chronic
immunosuppression.
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VASCULARIZED BONE MARROW
TRANSPLANTATION EXTENDS
SURVIVAL OF VASCULARIZED
SKIN ALLOGRAFTS
Izycki D., Osawa T., Ozmen S.,
Gozel Ulusal S., Engine Ulusal A.,
Mackiewicz A., Siemionow M.
Zaktad Immunologii Nowotwor6w AM
w Poznaniu, Department of Plastic Surgery,
The Cleveland Clinic Foundation
Purpose: Vascularized bone marrow
allotransplantation is known to be the most
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effective way of multilineage chimerism
induction in the experimental and clinical
models. In this study, we introduce
combined vascularized skin/vascularized
bone transplantation model (VSNB) to
evaluate the effect of the VB trans-
plantation on tolerance induction across
strong MHC barrier, under a~-TCRmAb
+CsA treatment protocol.
Methods: Thirty-six-transplantations
between ACI (RT1 a) donors to Lewis
(RT11) recipients were performed in three
experimental groups of six animals each.
In isograft control group and allograft
rejection control group no treatment was
applied. The experimental group III of
vascularized skin /vascularized bone
allograft TCRlCsA for 7 days only. The
efficacy of (VS/BM) was treated with ab
immunosuppressive treatment and the
level of chimerism in the peripheral blood
of recipients were determined by flow
cytometry (FC). Standard H+E technique
was applied for the evaluation of the grade
of graft rejection.
Results: The Isograft Control Group I
transplants survived indefinitely. In allo-
graft rejection control transplants were
rejected between 5 and 9 days post-trans-
plant. The survival time was significantly
(p<0.05) extended in the VS/BM group up
to 90-125 days after treatment cessation.
MLR revealed no response to the host and
donor antigens but strong reactivity to the
third party (BN) alloantigens. Two-color FC
analysis of the RT1 a antigen expression in
the peripheral blood of the VSBM
recipients confirmed the presence of the
donor specific chimerism ranged form 12%
to 25% at day 63 post-transplant. At day
63 post-transplant the skin biopsies from
VS/BM recipients revealed no signs of
rejection.
Conclusion: Transplantation of the
vascularized skin with vascularized bone
resulted in significant prolongation of the
allograft survival. Allotransplantation of the
vascularized bone with marrow natural
micro-anatomic environment increases of
the donor-derived stem and progenitor
cells engraftment resulted in the
establishment of the stable, donor specific
chimerism.
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DEVELOPMENT OF DONOR
SPECIFIC CHIMERISM AND
TOLERANCE IN COMPOSITE
TISSUE ALLOGRAFTS UNDER
AB-T CELL RECEPTOR MONO-
CLONAL ANTIBODY AND CYCLO-
SPORINE A TREATMENT PRO-
TOCOLS
Izycki D., Osawa T., Ozer K.,
Zielinski M., Siemionow M.
Department of Plastic Surgery,
The Cleveland Clinic Foundation
Purpose: Recently, we induced donor
specific tolerance to rat hind-limb allografts
under 35 days course of ab TCR mAb and
Cyc\osporine A. In this report, we inve-
stigated the role of shorter ab-TCR/CsA
protocols on the tolerance induction.
Materials and Methods: We performed
fifty-two hind-limb transplantations,
between Lewis-Brown-Norway (LBN, F1 )
donors and Lewis recipients to test the
impact of 21, 7 and 5 day protocols of
combined ab-TCR/CsA treatment on
tolerance induction. Donor specific
tolerance and immunocompetence were
tested by mixed lymphocyte reaction
(MLR) in vitro and by standard skin
grafting in vivo. The efficacy of immuno-
suppressive protocol and donor specific
chimerism was assessed by flow cyto-
metry.
Results: All transplants under 5, 7, and
21 days of combined ab-TCR/CsA therapy
survived over 350 days. Clinical tolerance
and immunocompetence were confirmed
by skin grafting in vivo and MLR in vitro.
Flow cytometry revealed· high levelot do-
nor chimerism in the peripheral blood of
the long term survivors.
Conclusion: The extention of survival
of limb allografts and allounresponsive-
ness were directly associated with the de-
velopment of stable chimerism in the tole-
rated recipients.
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